Key result
Among 127 patients with castration-resistant prostate cancer, sarcopenia (n=99) was an independent favorable prognostic factor for progression-free survival when treated with ARATs.
Why the study?
Does sarcopenia affect the progression-free survival and overall survival of patients with castration-resistant prostate cancer treated with androgen receptor axis-targeted therapies?
Cohort (n=127)
Yes
Does sarcopenia affect the progression-free survival and overall survival of patients with castration-resistant prostate cancer treated with androgen receptor axis-targeted therapies?
Sarcopenia may positively influence the therapeutic effects of androgen receptor axis-targeted therapies in patients with castration-resistant prostate cancer, leading to better progression-free survival.
Sarcopenia may aid PFS prognostication on ARATs in CRPC; hypothesis-generating and should not yet change practice.
No takes yet. Share an insight, caveat, or question.
Hiroshige et al. (2023) conducted a cohort in Castration-resistant prostate cancer (n=127). Sarcopenia vs. Non-sarcopenia was evaluated on Progression-free survival (PFS). Among 127 patients with castration-resistant prostate cancer, sarcopenia (n=99) was an independent favorable prognostic factor for progression-free survival when treated with ARATs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: